Avapritinib is a highly selective tyrosine kinase inhibitor for KIT D816V-mutant protein [18, 27] that has been found to significantly reduce symptoms and improve biomarkers of MC burden and quality of life in patients with ISM and advanced SM [18, 28]. This evidence concerns the gene KIT and systemic mastocytosis.